Literature DB >> 29197415

Variability in adherence to clinical practice guidelines and recommendations in COPD outpatients: a multi-level, cross-sectional analysis of the EPOCONSUL study.

Myriam Calle Rubio1, José Luis López-Campos2,3, Juan J Soler-Cataluña4, Bernardino Alcázar Navarrete5, Joan B Soriano6, José Miguel Rodríguez González-Moro7, Manuel E Fuentes Ferrer8, Juan Luis Rodríguez Hermosa9.   

Abstract

BACKGROUND: Clinical audits have reported considerable variability in COPD medical care and frequent inconsistencies with recommendations. The objectives of this study were to identify factors associated with a better adherence to clinical practice guidelines and to explore determinants of this variability at the the hospital level.
METHODS: EPOCONSUL is a Spanish nationwide clinical audit that evaluates the outpatient management of COPD. Multilevel logistic regression with two levels was performed to assess the relationships between individual and disease-related factors, as well as hospital characteristics.
RESULTS: A total of 4508 clinical records of COPD patients from 59 Spanish hospitals were evaluated. High variability was observed among hospitals in terms of medical care. Some of the patient's characteristics (airflow obstruction, degree of dyspnea, exacerbation risk, presence of comorbidities), the hospital factors (size and respiratory nurses available) and treatment at a specialized COPD outpatient clinic were identified as factors associated with a better adherence to recommendations, although this only explains a small proportion of the total variance.
CONCLUSION: To be treated at a specialized COPD outpatient clinic and some intrinsic patient characteristics were factors associated with a better adherence to guideline recommendations, although these variables were only explaining part of the high variability observed among hospitals in terms of COPD medical care.

Entities:  

Keywords:  Adherence to recommendations; Chronic obstructive pulmonary disease; Clinical audit; Clinical practice guidelines; Medical care

Mesh:

Year:  2017        PMID: 29197415      PMCID: PMC5712134          DOI: 10.1186/s12931-017-0685-8

Source DB:  PubMed          Journal:  Respir Res        ISSN: 1465-9921


Background

Chronic obstructive pulmonary disease (COPD) is one of the most frequent reasons for seeking medical attention and accounts for 10% of primary care and 30% of outpatient respiratory care visits [1]. Patients with this condition have a high morbidity and mortality [2, 3]. For these reasons, there are a number of clinical practice guidelines (CPG) aimed to systemize medical care for COPD [4-7]. However, the real-life implementation of these CPG is low [8, 9]. Clinical audits have emerged as an overarching tool to measure the adequacy of clinical practice and feedback is being used to improve health care [10]. For more than 12 years, some countries have been auditing the quality of their in-hospital COPD management in a systematic way [11-13]. However, we have less evidence regarding outpatient care, and the few existing studies only explored certain aspects, such as the diagnosis or the prescription pattern, showing us outpatient care is far from perfect [14-18] with considerable variability in COPD medical care and frequent inconsistencies with CPG recommendations. The EPOCONSUL study is the first national audit to evaluate the adequacy of medical care according to CPG in Spain in COPD patients treated at outpatient respiratory clinics. The study confirmed significant variations in adherence to CPG recommendations between centers [19]. The objective of our work has been analyze the variability and to identify factors associated with adherence to current recommendations for COPD clinical practice guidelines for outpatients in Spain.

Methods

The methodology of the EPOCONSUL audit has been extensively described elsewhere [19]. Briefly, the COPD audit promoted by the Spanish Society of Pneumology and Thoracic Surgery (SEPAR) was designed to evaluate clinical practice as well as clinical and organizational factors related to managing patients with COPD across Spain. It was designed as an observational non-interventional cross-sectional study. Recruitment was intermittent during the year (May 2014–May 2015). Every 2 months each investigator recruited clinical records of the first 10 patients identified as diagnosed with COPD and seen in the outpatient respiratory clinic. Subsequently, patients identified were reevaluated to determine if they met the inclusion/exclusion criteria described in Appendix 1. The sampling process was detailed in an epidemiology flow chart and described in Appendix 2. The information collected was historical in nature for the clinical data of the last and previous visits, and the information about hospital resources was concurrent. As described in the methodological research paper [19], in order to evaluate the degree of current CPG implementation of the main statements according to the 2012 Spanish National Guidelines for COPD care (GesEPOC) and the 2013 Global initiative for chronic Obstructive Lung Disease (GOLD), we established fulfilling ≥ 50% of criteria for good clinical practice evaluated in each category (clinical evaluation of the patient, COPD evaluation and therapeutic intervention) as the cut-off point. From the 175 public hospitals in the National Health System invited from the Spanish Society of Pneumology and Thoracic Surgery, 59 participated (33.3%). The estimated reference population for the EPOCONSUL study was 18,104,350 inhabitants, representing 39% of the Spanish population. The distribution of hospitals in the different regions and the population covered by those hospitals are detailed in Appendix 3 and participating investigators are included in Appendix 4. In order to compare hospitals, these were divided in two types of center according to their size (small or large) as measured by: the number of beds per center ≥ 500, the number of inpatient respiratory beds ≥ 20, the number of pulmonology staff members ≥ 5, and the number of annual outpatient respiratory visits ≥ 10,000. All the criteria are necessary to be considered large. The protocol was approved by the Ethics Committee of the Hospital Clínico San Carlos (Madrid, Spain; internal code 14/030-E). Additionally, according to current research laws in Spain, the ethics committee at each participating hospital evaluated and agreed to the study protocol. The need for informed consent was waived because ours is a clinical audit, beside the non-interventional nature of the study, the anonymization of data and the need to blindly evaluate the clinical performance. This circumstance was clearly explained in the protocol, and the ethical committees approved this procedure. To avoid modifications to the usual clinical practice and preserve the blinding of the clinical performance evaluation, the medical staff responsible for the outpatient respiratory clinic was not informed about the audit. Data was entered remotely at each participating location to a centrally-controlled server.

Statistical analysis

Descriptive results are presented both at the patient and hospital level. Qualitative variables were summarized by their frequency distribution as well as quantitative variables by their median, interquartile range (IQR) and minimum–maximum. The differences between hospital resources and characteristics according to size (small vs large) were evaluated using χ2 tests for categorical data, while the non-parametric Mann-Whitney test was used for continuous data. Significance of variability by area/hospital was explored by the Kruskal–Wallis or chi-square tests. With regard to missing data, after performing data cleansing to identify and correct missing and extremely unlikely values, the data was included in the analysis as missing information. Three dependent variables were generated to evaluate the degree of CPG implementation; criteria of good clinical practice were categorized into: fulfilling three criteria at the clinical evaluation, fulfilling four criteria at the COPD evaluation, and fulfilling three criteria at the therapeutic intervention. The association between each independent variable (patient characteristics, hospital resources and work organization) and each of the dependent variables was assessed by calculating the crude odds ratio (OR) via multilevel bivariate regression analysis. Each multilevel analysis included two levels: the individual or patient level (level 1), and the hospital level (level 2). It was developed in four consecutive steps: (1) Model 1 (empty model) which included only the dependent variable and the hospital-cluster effect; (2) random effects Model 2, which included the hospital variables; (3) random effects Model 3, which included the patient variables; (4) random effects Model 4, which included the patient and hospital variables in order to obtain an overall multivariable model. Candidate predictors with a value of p < 0.10 in the univariate analysis were accepted for inclusion in the multivariate analysis in model 2 and 3. Variables were removed from the model when the p-value exceeded 0.10 and were kept in the final model when less than 0.05. The independent predictor variables included in Model 4 were those selected in the last step in Models 2 and 3. The coefficients of the predictor variables were transformed into OR, with 95% confidence intervals (CI). The hospital cluster effect was evaluated and quantified by two indicators: 1) the intra-cluster correlation coefficient (ICC) which represents the proportion of the variance attributable to the clustering effect and 2) the median odds ratio (MOR). The MOR can be interpreted as the median increased odds of reaching the outcome if an individual was admitted to another hospital with a greater risk of that outcome. All analyses were performed using STATA 12.0 software. Statistical significance was assumed as p < 0.05.

Results

A total of 17,893 clinical records of patients treated in outpatient respiratory clinics were evaluated during the study period and 5726 clinical records of patients presumably diagnosed with COPD were selected. Of them, 4508 patients were audited from 59 hospitals, for having all the inclusion criteria and none of the exclusion criteria. The sampling process was detailed in an epidemiology flow chart and described in Appendix 2.

Center characteristics

The hospital characteristics and respiratory unit resources are summarized in Table 1. Large hospitals constituted 54% of centers. The majority participating centers were public (93.2%), university hospitals (83.1%) and had a pulmonary resident available (67.8%). Although the larger hospitals had more staff, the length of the outpatient follow-up visit was similar. There were few centers with a specialized COPD outpatient clinic (47.5%) and outpatient respiratory nursing clinic (45.8%), regardless of hospital size.
Table 1

Characteristics of the participating hospitals and resources of the respiratory units

AllSmall hospitalLarge hospital P
Number of participating hospitals, n 592732
Public hospital (%)93.285.21000.039
University hospital (%)83.163100<  0.001
Beds per center ≥ 500 (%)62.718.5100< 0.001
Beds per center, median (P25–75)651 (349–943)332 (231–436)903 (702–1199)< 0.001
Hospital with a respiratory ward (%)83.163100< 0.001
Number of inpatient respiratory beds ≥ 20 (%)83.752.9100< 0.001
Number of pulmonology staff members ≥ 5 (%)81.459.3100< 0.001
Number of pulmonology staff members, median (P25–75)10 (5–13)5 (2–8)13 (10–16)< 0.001
Pulmonology residents available (%)67.833.396.9< 0.001
Number of annual outpatient respiratory visits, median (IQR)15,447 (12004–25,680)12,004 (4355–13,556)23,985 (16070–27,838)< 0.001
Number of annual outpatient respiratory visits ≥ 10,000 (%)81.459.3100< 0.001
≥ 15 min of follow-up at general outpatient respiratory visit (%)44.148.140.60.562
Specialized COPD outpatient clinic available (%)47.540.753.10.343
≥ 15 min of follow-up at specialized COPD outpatient visit (%)64.474.156.30.154
Outpatient respiratory nursing clinic availability (%)45.844.446.90.852
Functional respiratory laboratory available (%)
 - Spirometry1001001001
 - Diffusing capacity1001001001
 - Plethysmography1001001001
 - Respiratory muscle strength84.766.7100< 0.001
 - 6MWT available94.988.91000.090
 - Cardiopulmonary exercise testing available62.740.781.30.001
Inhalation technique educational program available (%)30.515.648.10.007
Respiratory rehabilitation program available (%)74.666.781.30.2
 - Hospital-based61.461.161.50.617
 - Home-based6.811.13.8
 - Mixed31.827.834.6

Data are presented as median (CI 95%), unless stated otherwise. Dichotomous variables are expressed as number and/or percent. p † calculated by the Kruskal–Wallis or Chi-square test, depending on the nature of the variable

Characteristics of the participating hospitals and resources of the respiratory units Data are presented as median (CI 95%), unless stated otherwise. Dichotomous variables are expressed as number and/or percent. p † calculated by the Kruskal–Wallis or Chi-square test, depending on the nature of the variable

Audited patient characteristics and clinical conditions

The main characteristics of the patients evaluated are presented in Table 2.
Table 2

Clinical characteristics of the audited cases

Patients (N = 4508)Hospitals (N = 59) p
N % or median (IQR)MedianIQR
Sex (male), (%)4.5088687.582.1–93.2< 0.001
Age (years), median (P25–75)4.50869.7 (63–77.7)7069–72< 0.001
  ≤ 55 (%)8.58.25.8–11.7
 56–69 (%)38.738.130–42.6
  ≥ 70 (%)52.853.347.1–61.7
Pack-years, median (P25–75)4.50847 (34–70)4540–51< 0.001
Active smokers, (%)4.50823.12218–29< 0.001
BMI kg/m2, median (P25–75)4.50828.0 (24.4–31.1)27.826.6–28.50.03
  ≤ 21 (%)7.16.74.1–9.2
 22–29 (%)60.858.856.1–64
  ≥ 30 (%)32.131.426.2–37.7
Charlson index, median (P25–75)4.5082 (1–4)22–3< 0.001
  ≥ 3 (%)44.944.540–56.6
Dyspnea (MRC-m)4.508< 0.001
 0 + 1 (%)27.323.811.6–44.5
  ≥ 2 (%)41.438.328.3–54
 Missing (%)13.28.91.6–21.6
 Level of dyspnea not referred to (%)18.111.63.3–30
CAT questionnaire >10, (%)86962.46447.9–83.8< 0.001
Chronic bronchitis criteria, (%)4.50841.74128.3–51< 0.001
Chronic colonization, (%)4.5086.053.2–8.3< 0.001
Symptoms suggestive of asthma,(%)4.50826.518.310.8–35< 0.001
% FEV1, median (P25–75)4.50850 (37–63)5147–540.03
  <  50%49.145.541.5–53.3
 50–64%2828.522.3–31.7
  ≥ 65%22.923.815–30
Number of moderate/severe exacerbations in the last year, median (P25–75)3.1961.1 (0–2)10–10.03
Number of hospital admissions in the last year, median (P25–75)45080.5 (0–1)00–00.03
BODE value, median (P25–75)6323.9 (3–5)4.53–5.5< 0.001
GOLD group985< 0.001
 A (%)22.714.30–25.9
 B (%)18.716.70–24.1
 C (%)18.7209.8–33.3
 D (%)39.94023.5–55.6
GesEPOC Phenotype4.508< 0.001
 - Non-exacerbator, (%)27.524.411.4–28
 - Exacerbator, (%)18.815.73.4–22
 - Missing, (%)53.752.344–58.9
LAMA monotherapy, (%)4.39110.0104.8–15.30.03
LAMA-LABA combination, (%)4.39122.720.314.5–27.9< 0.001
LABA+ ICS combination, (%)4.3917.76.73.4–9.80.03
Triple therapy (LAMA + LABA + CSI), (%)4.39149.150.839.3–60.3< 0.001
Long-term oxygen therapy, (%)4.50826.6%2517.1–33.30.03
Home ventilation, (%)4.5087.5%52.5–11.6< 0.001
Respiratory rehabilitation, (%)4.508950–11.8< 0.001
Respiratory care follow-up (years), (%)4.5084 (2–7)43.5–50.03

Dichotomous variables are expressed as n and percentage. Average value expressed as median (P25–75). The variability was expressed using the interquartile range (IQR) of median. †Calculated for the variability between centers using test de Kruskal–Wallis or chi-square test, depending on the nature of the variable

Abbreviations: LABA long-acting beta-2 agonists, LAMA long-acting antimuscarinic agents, ICS inhaled corticosteroids, GOLD Global Initiative for Chronic Obstructive Lung Disease, GesEPOC Spanish National Guidelines for COPD, CAT COPD Assessment Test

Clinical characteristics of the audited cases Dichotomous variables are expressed as n and percentage. Average value expressed as median (P25–75). The variability was expressed using the interquartile range (IQR) of median. †Calculated for the variability between centers using test de Kruskal–Wallis or chi-square test, depending on the nature of the variable Abbreviations: LABA long-acting beta-2 agonists, LAMA long-acting antimuscarinic agents, ICS inhaled corticosteroids, GOLD Global Initiative for Chronic Obstructive Lung Disease, GesEPOC Spanish National Guidelines for COPD, CAT COPD Assessment Test

Adequacy of medical care according to CPG

Adherence to the main CPG statements is summarized in Table 3. There was a significant variation between hospitals, with a better adherence to the statements in the clinical evaluation category, with three out of six criteria fulfilled in 65.5% of the patients.
Table 3

Adherence to recommendations (GOLD and GesEPOC) evaluated in the study and classified in three categories: clinical evaluation of the patient, COPD evaluation and therapeutic interventions. The number of criteria or quality standards fulfilled was analyzed in each category

Criteria of good clinical practice evaluated in EPOCONSULN of criteria fulfilledPatients (N = 4.508) %Hospitals (N = 59) MedianInter-hospital range p
Clinical evaluation category
1. Was degree of dyspnea evaluated during current visit? 2. Was the number of hospital admissions in the last 12 months collected during current visit? 3. Was the number of moderate or severe exacerbations in the last 12 months collected during current visit? 4. Was current smoking habit information collected? 5. Was regular exercise data collected during current visit? 6. Are comorbidities identified in the clinical record?6 criteria18.314.60–100< 0.001
>3 criteria65.57011.7–100< 0.001
≤3 criteria34.5300–88.3< 0.001
COPD evaluation category
1. Alfa-1-antitrypsin serum level determination available? 2. COPD severity defined in the report? 3. COPD GOLD type defined in the report? 4. COPD phenotype according to GesEPOC defined in the report? 5. 6MWT carried out on any occasion? 6. Diffusion capacity measured on any occasion? 7. Lung volumes measured on any occasion? 8. Chest CT scan carried out on any occasion in exacerbator phenotype?8 criteria1.500–14.6< 0.001
> 4 criteria30.1270–89.3< 0.001
≤ 4 criteria69.97310.7–100< 0.001
Therapeutic intervention category
1. Is treatment adherence evaluated in any way? 2. Is inhalation technique evaluated in any way? 3. Is Pneumococcal vaccination recommended? 4. Is exercise advised during the visit? 5. Have arterial blood gases been measured on any occasion in patients on long-term oxygen therapy? 6. Is a specific intervention for smoking cessation for active smokers offered?6 criteria9.33.30–45.1< 0.001
> 3 criteria22.412.50–100< 0.001
≤ 3 criteria77.687.50–100< 0.001

Dichotomous variables are expressed as n and percentage. The variability between centers was expressed using the inter-hospital range (min–max). p † was calculated for the variability between centers using the Kruskal–Wallis or Chi-square tests, depending on the nature of the variable

Adherence to recommendations (GOLD and GesEPOC) evaluated in the study and classified in three categories: clinical evaluation of the patient, COPD evaluation and therapeutic interventions. The number of criteria or quality standards fulfilled was analyzed in each category Dichotomous variables are expressed as n and percentage. The variability between centers was expressed using the inter-hospital range (min–max). p † was calculated for the variability between centers using the Kruskal–Wallis or Chi-square tests, depending on the nature of the variable

Adherence to CPG recommendations based on patient and center characteristics

The bivariate association between adherence to the main CPG statements and the variables related to hospital and patient characteristics is summarized in Appendix 5. A major number of the patient-level variables were associated with adherence, whereas the majority of center-level variables were not.

Multilevel variability analysis of adherence to CPG recommendations

For the adherence to the statements in the clinical evaluation category, fulfillment of at least three criteria, the percentage of the total variability attributable to the hospital-cluster effect was 36%. The empty model exhibited a significant cluster effect (ICC = 0.36) and cluster heterogeneity (MOR = 3.73). In the adjusted model, being an active smoker, having a Charlson index ≥ 3, undergoing ≥ 1 hospitalization for COPD in the past year and being treated at a specialized COPD outpatient clinic was positively associated. Only one variable linked to the hospital level (large hospital) was retained in the model as a predictor, but was unfavorable (Table 4). The inclusion of all predictors further reduced the residual between-hospital cluster variability. The ICC and MOR dropped to 0.31 and 3.26, respectively (Table 4). Some unrecorded values (COPD phenotype missing) showed significant associations, which is naturally open to interpretation.
Table 4

Multilevel logistic regression models of the variability in adherence to good clinical practice criteria for three categories: clinical evaluation of the patient, disease evaluation and therapeutic interventions

Intra-class correlation (ICC)Median Odds Ratio (MOR)VariablesAdjusted OR (95% CI) p
Adherence to good clinical practice criteria in clinical evaluation (≥3 criteria fulfilled)
 Empty model 10.366703.73040
 Model 2: center variables1 0.318663.26487
 Model 3: patient variables2 0.368313.74755
 Full model 4 (center and patient)0.318503.26345Large hospital0.40 (0.21–0.79)0.008
Outpatient respiratory nursing clinic available2.47 (1.26–4.83)0.008
Active smokers1.32 (1.10–1.58)0.003
Charlson index ≥31.35 (1.15–1.59)< 0.001
Number of hospital admissions in the last year ≥16.33 (5.02–7.98)< 0.001
GesEPOC phenotype
 Not exacerbator (reference)
 Exacerbator0.79 (0.61–1.101)0.063
 Missing0.36 (0.29–0.44)< 0.001
To be taken care in specialized COPD outpatient clinic)2.10 (1.56–2.72)< 0.001
1: included variables in the final center model: large hospital and outpatient respiratory nursing clinic available2: included variables in the final patient model: active smokers, Charlson index ≥3, number of hospital admissions in the last year ≥1, to be taken care in specialized COPD outpatient clinic and GesEPOC phenotype exacerbator.
Adherence to good clinical practice criteria in COPD evaluation (≥4 criteria fulfilling)
 Empty model 10.303433.13266
 Model 2: center variables1 0.266842.83994
 Model 3: patient variables2 0.291003.02953
 Full model 4 (center and patient)0.244132.67316Respiratory ward not available (reference)
Respiratory ward < 20 beds7.09 (2.53–9.90)< 0.001
Respiratory ward ≥20 beds3.00 (1.37–6.60)0.006
Age ≤ 551.58 (1.19–2.09)0.001
Sex (male)0.77 (0.61–0.96)0.022
Charlson index ≥30.80 (0.68–0.94)0.008
FEV1 <  50%1.68 (1.42–1.99)< 0.001
Dyspnea (MRC-m)
 0–1 (reference)
  ≥ 21.39 (1.13–1.72)0.002
 Missing0.69 (0.51–0.93)0.017
 Level of dyspnea not referred to0.65 (0.49–0.86)0.003
GesEPOC phenotype
 Non-exacerbator (reference)
 Exacerbator1.16 (0.93–1.44)0.185
 Missing0.17 (0.14–0.21)< 0.001
Treatment at a specialized COPD outpatient clinic3.25 (2.49–4.23)< 0.001
1: variables included in the final center model: in-patient respiratory clinic ≥20 present and specialized COPD outpatient clinic available.2: variables included in the final patient model: age ≤ 55, gender (male), Charlson index ≥3, FEV1 <  50%, dyspnea, GesEPOC exacerbator phenotype and being treated in specialized COPD outpatient clinic.
Adherence to good clinical practice criteria in therapeutic intervention (≥3 criteria fulfilled)
 Empty model 10.521696.09155
 Model 2: center variables1 0.469355.08927
 Model 3: patient variables2 0.499945.64024
 Full model 4 (center and patient)0.447314.74211University hospital0.26 (0.08–0.85)0.026
Outpatient respiratory nursing clinic availability3.69 (1.50–9.11)0.005
Age ≤ 550.60 (0.42–0.86)< 0.005
Sex (male)0.72 (0.55–0.93)0.014
Charlson index ≥31.19 (0.99–1.42)0.062
Number of hospital admissions in the last year ≥11.71 (1.38–2.11)< 0.001
GesEPOC phenotype
 Non-exacerbator (reference)
 Exacerbator0.90 (0.71–1.15)0.404
 Missing0.36 (0.29–0.46)< 0.001
Treatment at a specialized COPD outpatient clinic2.61 (2.01–3.40)<0.001
1: variables included in the final center model: university hospital and outpatient respiratory nursing clinic availability2: variables included in the final patient model: age ≤ 55, gender (male), Charlson index ≥3, number of hospital admissions in the last year ≥1, GesEPOC exacerbator phenotype and being treated in specialized COPD outpatient clinic
Multilevel logistic regression models of the variability in adherence to good clinical practice criteria for three categories: clinical evaluation of the patient, disease evaluation and therapeutic interventions For COPD evaluation category, fulfillment of at least four criteria, the empty model displayed an ICC of 0.30 and a MOR of 3.13 (Table 4). In the adjusted model, an age of ≤ 55 years, FEV1 < 50%, dyspnea ≥ 2 MRC-m and being treated at a specialized COPD outpatient clinic were positively associated with better adherence to CPG recommendations. However, being male and having a Charlson index ≥ 3 were retained as predictors of worse adherence. Some unrecorded values (COPD phenotype missing, dyspnea missing, or level of dyspnea not referred to) showed a significant negative association. Only one variable linked to the hospital level (i.e. respiratory ward availability) was retained as a predictor of better adherence. The inclusion of this predictor further reduced the between-hospital cluster variability. The ICC and MOR dropped to 0.24 and 2.67, respectively. For therapeutic intervention category, fulfillment of at least three criteria, the empty model displayed an ICC of 0.52 and a MOR of 6.09. A Charlson index ≥ 3, undergoing ≥ 1 hospitalizations in the past year, being treated at a specialized COPD outpatient clinic, and outpatient respiratory nursing clinic availability were associated with better adherence to the recommendations. Meanwhile, being male, being ≤ 55 years old and being a university hospital were all associated with worse adherence. The inclusion of these predictors further reduced the between-hospital cluster variability. The ICC and MOR dropped to 0.44 and 4.74, respectively (Table 4).

Discussion

The present study constitutes one of the few research papers in the literature that analyze the variability in adherence to current recommendations for COPD clinical practice guidelines for outpatients in Spain. In our analysis, we aimed to study the variables associated with this variability. This study shows that accounting for the hospital cluster effect, the patient-level and hospital-level predictor variables, partly reduced the unexplained between-hospital variation in adherence. Additionally, it identified a number of variables as predictors of better adherence at the patient and hospital levels. Most predictors were linked to patient characteristics (patient-level) and the type of respiratory clinic in which the patient was treated (general clinic or specialized COPD outpatient clinic). Being treated at a specialized COPD outpatient clinic was associated with a higher likelihood of adherence to guidelines in the three categories evaluated, and was considered to be of greater importance, compared with the cluster effect, in explaining the between-hospital outcome variations. This is an interesting result, since less than half of the centers had specialized COPD outpatient clinics. In addition, the time available at specialized COPD outpatient clinics to treat the patient was the same as the general outpatient respiratory visit and there was no support nurse. Consequently, this could be considered a proxy for the experience, knowledge and interest of department physicians in the management of COPD patients. Also, some unrecorded values (COPD phenotype missing and level of dyspnea missing) showed a statistically significant negative association, which are naturally open to interpretation. The clinical COPD phenotype according to the Spanish National Guideline for COPD (GesEPOC) was collected in 46.3% of the audited patients. Only 2 (outpatient respiratory nursing clinic and a respiratory ward availability) of the 46 hospital-level variables examined were retained in the model associated with a higher likelihood of implementing CPG recommendations. On the contrary, being a university hospital or large hospital were negatively associated factors. Nevertheless, given the small amount of cluster variability left unexplained in the analysis, it is unlikely that relevant hospital-level variables were not revealed. It’s possible that this finding is the result of a relative small hospital sample size (N = 59). Thus, medical care in COPD does not require complex interventions and the majority of respiratory units offered a functional respiratory laboratory. We must consider the fact that this study did not include information about work organization such as COPD clinical management protocol availability or electronic/digital information availability. It also did not include the number of respiratory physicians or respiratory nurses available in the area around the clinic or the professional experience of treating physicians, which might explain a proportion of the total variance due to the center effect. Our findings are similar to those of previous studies that have demonstrated significant variability in the processes of COPD care. In the European COPD Audit [13], a considerable variability in recommendation guideline suitability was described and only hospital characteristics were related to a minority of indicators. The adherence to guidelines also varied with hospital size, but the differences were small and inconsistent. Previous studies have shown adherence to clinical guidelines was a strong predictor of a favorable outcome. Roberts et al. [11] have suggested that a hospital’s resources are potential components of the unexplained variation in outcomes. A greater number of medical and nursing staff was identified as a protective factor for intra-hospital mortality. In AUDIPOC Spain [12, 20], the large hospital COPD volume and the number of COPD patients admitted to the hospital the year prior to admission was identified as a predictor of a favourable outcome. In our study, a large component of center-related variance remained unexplained, suggesting that the clinical profile of patients included in the study also varied markedly among hospitals. It is important to remember that recommendation guidelines are evidence-based and aimed to systemize medical care, but the clinical presentation of COPD is variable [21]. Our study has several strengths and limitations. The main strength is its sample size that accounts for 39% of the Spanish population. Nevertheless, the limitations to be considered are the fact that the selection of participating centers was not random and hospital participation was voluntary based on their interest to participate. Also, clinical records were used as the data source, so some missing and inconsistent values were unavoidable. Despite these limitations, we believe that this dataset represents the largest available comparative survey of Spanish centers.

Conclusions

High variability was observed among hospitals in terms of medical care. Some of the patient’s characteristics (airflow obstruction, degree of dyspnea, exacerbation risk, presence of comorbidities) and the type of respiratory clinic in which the patient was treated (specialized COPD outpatient clinic) were identified as factors associated with a better adherence to recommendations, though a great part of the variability among center cannot be explained. This suggests that there is a significant inconsistency among centers in the implementation of clinical guidelines. This information must be accounted for by health care professionals and administrators, in order to establish better clinical practice by means of the medical care in the specialized COPD outpatient clinic and the implementation of evidence-based best clinical practice guidelines that could facilitate a uniform approach to COPD patients as outpatients, thereby both improving patient outcomes and optimizing medical resources.
Table 5

The inclusion criteria and exclusion criteria

The inclusion criteria- patients aged ≥40 years- smokers or ex-smokers (of at least 10 pack-years)- COPD diagnosed on the basis of spirometric tests (FEV1/FVC post-bronchodilation < 0.7 or FEV1/FVC pre-bronchodilation < 0.7 and FEV1 ≥ 80%, if there is no bronchodilation reversibility testing available
The exclusion criteria- lack of follow-up for at least 1 year in a respiratory outpatient clinic- participating in a clinical trial
Table 6

Participating hospitals and catchment population by Autonomous Community

Region of SpainNumber of participating hospitalsPopulation assigned for admissionPopulation of the regionCatchment population of the EPOCONSUL study (%)
Andalucía102.784.0838.424.10233
Aragón2597.0001.346.29344.3
Asturias1250.0001.081.48723.1
Islas Baleares2575.0001.113.11451.6
País Vasco41.285.0002.184.60658.8
Islas Canarias1700.0002.126.76932.9
Cantabria2395.000593.12166.6
Castilla y la Mancha41.186.0142.115.33456
Castilla y León41.119.0862.558.46343.7
Cataluña51.657.0007.539.61822
Extremadura1273.9771.109.36724.7
Galicia2970.0002.795.42234.7
Madrid113.484.9956.489.68053.7
Murcia3770.1751.470.06952.3
Navarra1517.020.642.05180.5
Valencia61.540.0005.117.19030
TOTAL5918.104.35046 .064 .63539.3

Data are presented as Numbers. The percentages refer to the total population number

There was no participating hospital in La Rioja, the 17th Autonomous Community in Spain

Table 7

Logistic regression bivariate analysis (adherence to good clinical practice criteria in three categories: clinical evaluation of the patient, COPD evaluation and therapeutic interventions)

PatientsClinical evaluation ≥ 3 criteria fulfilled OR (95%CI) p CentersClinical evaluation ≥ 3 criteria fulfilled OR (95% CI) p
Age (≤55 years)1.01 (0.78–1.31)0.89Large hospital0.44 (0.21–0.89)0.024
Sex (male)0.96 (0.78–1.17)0.70University hospital0.32 (0.12–0.82)0.018
Active smokers1.25 (1.05–1.48)0.011Beds per center ≥5000.57 (0.27–1.22)0.152
Dyspnea (MRC-m)Respiratory ward not availableReference
 0–1Respiratory ward <20 beds0.90 (0.24–3.32)0.876
 ≥2ReferenceRespiratory ward ≥20 beds0.51 (0.19–1.35)0.178
 Missing1.02 (0.83–1.26)0.797
 Level of dyspnea not referred to0.24 (0.19–0.31)<0.001
0.11 (0.09–0.15)<0.001
FEV1< 50%1.24 (1.07–1.43)0.004Number of pulmonology staff members ≥ 50.80 (0.35–1.86)0.620
Charlson index ≥ 31.45 (1.25–1.69)<0.001Pulmonology residents present0.90 (0.41–1.99)0.806
Number of hospital admissions in the last year ≥ 16.45 (5.16–8.07)<0.001Number of annual outpatient respiratory visits ≥ 10,0000.45 (0.17–1.19)0.109
GesEPOC phenotype≥ 15 min of follow-up at general outpatient respiratory visit2.34 (1.13–4.83)0.021
 Non-exacerbatorReference
 Exacerbator1.26 (1.00–1.59)0.048
 Missing0.40 (0.33–0.49)<0.001
Triple inhalation therapy1.01 (0.87–1.17)0.872Specialized COPD outpatient clinic available1.07 (0.51–2.22)0.850
Treatment at a specialized COPD outpatient clinic2.49 (1.91–3.23)<0.001Outpatient respiratory nursing clinic availability2.47 (1.23–4.97)0.011
Inhalation technique educational program available1.61 (0.73–3.55)0.234
PatientsCOPD evaluation ≥4 criteria fulfilled OR (95%CI) p CentersCOPD evaluation ≥4 criteria fulfilled OR (95%CI) p
Age (≤55 years)1.68 (1.31–2.14)<0.001Large hospital1.25 (0.66–2.39)0.484
Sex (male)0.75 (0.61–0.92)0.006University hospital1.16 (0.49–2.74)0.729
Active smokers1.01 (0.82–0.85)0.824Beds per center ≥5001.65 (0.85–3.20)0.136
Dyspnea (MRC-m)Respiratory ward not availableReference
 0–1Respiratory ward <20 beds4.23 (1.39–12.86)0.011
  ≥2ReferenceRespiratory ward ≥20 beds2.23 (0.96–5.19)0.062
 Missing1.53 (1.28–1.84)<0.001
 Level of dyspnea not referred to0.51 (0.38–0.68)<0.001
0.54 (0.41–0.69)<0.001
FEV1<50%1.80 (1.55–2.08)<0.001Number of pulmonology staff members ≥51.44 (0.69–3.00)0.324
Charlson index ≥30.80 (0.69–0.92)0.003Pulmonology residents present1.69 (0.85–3.37)0.129
Number of hospital admissions in the last year ≥11.30 (1.10–1.55)0.002Number of annual outpatient respiratory visits ≥10,0001.82 (0.78–4.25)0.165
GesEPOC phenotype≥ 15 min of follow-up at general outpatient respiratory visit1.06 (0.54–2.09)0.845
 Non-exacerbatorReference
 Exacerbator1.38 (1.13–1.69)0.001
 Missing0.16 (0.13–0.20)<0.001
Triple inhalation therapy1.37 (1.18–1.60)<0.001Specialized COPD outpatient clinic available1.77 (0.94–3.31)0.073
Treatment at a specialized COPD outpatient clinic4.44 (3.48–5.68)<0.001Outpatient respiratory nursing clinic availability1.57 (0.83–2.95)0.158
Inhalation technique educational program available1.91 (0.97–3.75)0.058
PatientsTherapeutic intervention ≥3 criteria fulfilled OR (95%CI) p CentersTherapeutic intervention ≥3 criteria fulfilled OR (95%CI) p
Age (≤55 years)0.62 (0.44–0.87)0.007Large hospital0.46 (0.16–1.25)0.130
Sex (male)0.79 (0.61–1.02)0.074University hospital0.32 (0.08–1.17)0.087
Active smokers0.98 (0.80–1.20)0.894Beds per centre ≥5000.78 (0.27–2.25)0.656
Dyspnea (MRC-m)Respiratory ward not availableReference
 0–1Reference0.26 (0.04–1.66)0.158
  ≥21.10 (0.90–1.35)0.317Respiratory ward <20 beds0.32 (0.08–1.19)0.090
 Missing0.09 (0.05–0.15)<0.001Respiratory ward ≥20 beds
 Level of dyspnea not referred to0.24 (0.17–0.34)<0.001
FEV1<50%1.32 (1.07–1.63)0.008Number of pulmonology staff members ≥50.41 (0.13–1.27)0.125
Charlson index ≥31.23 (1.04–1.46)0.016Pulmonology residents present0.87 (0.29–2.61)0.813
Number of hospital admissions in the last year ≥11.83 (1.50–2.23)0.000Number of annual outpatient respiratory visits ≥10,0000.29 (0.08–1.06)0.062
GesEPOC phenotype≥ 15 min of follow-up at general outpatient respiratory visit1.09 (0.37–3.20)0.862
 Non-exacerbatorReference
 Exacerbator1.10 (0.87–1.38)0.414
 Missing0.37 (0.30–0.46)<0.001
Triple inhalation therapy1.02 (0.85–1.21)0.812Specialized COPD outpatient clinic available2.14 (0.79–5.79)0.133
Treatment at a specialized COPD outpatient clinic2.95 (2.28–3.83)<0.001Outpatient respiratory nursing clinic availability3.36 (1.27–8.84)0.014
Inhalation technique educational program available3.55 (1.25–10.07)0.017
  20 in total

1.  Acute exacerbations of COPD in the United States: inpatient burden and predictors of costs and mortality.

Authors:  Prasadini N Perera; Edward P Armstrong; Duane L Sherrill; Grant H Skrepnek
Journal:  COPD       Date:  2012-03-12       Impact factor: 2.409

2.  Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper.

Authors:  B R Celli; W MacNee
Journal:  Eur Respir J       Date:  2004-06       Impact factor: 16.671

3.  Variability of hospital resources for acute care of COPD patients: the European COPD Audit.

Authors:  Jose Luis López-Campos; Sylvia Hartl; Francisco Pozo-Rodriguez; C Michael Roberts
Journal:  Eur Respir J       Date:  2013-08-29       Impact factor: 16.671

4.  [Health-care quality standards in chronic obstructive pulmonary disease].

Authors:  Juan José Soler-Cataluña; Myriam Calle; Borja G Cosío; José María Marín; Eduard Monsó; Inmaculada Alfageme
Journal:  Arch Bronconeumol       Date:  2009-03-21       Impact factor: 4.872

5.  Current guidelines have limited applicability to patients with comorbid conditions: a systematic analysis of evidence-based guidelines.

Authors:  Marjolein Lugtenberg; Jako S Burgers; Carolyn Clancy; Gert P Westert; Eric C Schneider
Journal:  PLoS One       Date:  2011-10-20       Impact factor: 3.240

Review 6.  Implementing chronic care for COPD: planned visits, care coordination, and patient empowerment for improved outcomes.

Authors:  Len Fromer
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2011-11-21

7.  Guideline Adherence in Outpatient Clinics for Chronic Obstructive Pulmonary Disease: Results from a Clinical Audit.

Authors:  Jose L López-Campos; Maria Abad Arranz; Carmen Calero-Acuña; Fernando Romero-Valero; Ruth Ayerbe-García; Antonio Hidalgo-Molina; Ricardo I Aguilar-Pérez-Grovas; Francisco García-Gil; Francisco Casas-Maldonado; Laura Caballero-Ballesteros; María Sánchez-Palop; Dolores Pérez-Tejero; Alejandro Segado; Jose Calvo-Bonachera; Bárbara Hernández-Sierra; Adolfo Doménech; Macarena Arroyo-Varela; Francisco González-Vargas; Juan J Cruz-Rueda
Journal:  PLoS One       Date:  2016-03-17       Impact factor: 3.240

8.  Determinants of between-hospital variations in outcomes for patients admitted with COPD exacerbations: findings from a nationwide clinical audit (AUDIPOC) in Spain.

Authors:  F Pozo-Rodríguez; A Castro-Acosta; C J Alvarez; J L López-Campos; A Forte; A López-Quilez; A Agustí; V Abraira
Journal:  Int J Clin Pract       Date:  2015-02-04       Impact factor: 2.503

9.  Audit on the appropriateness of integrated COPD management: the "ALT-BPCO" project.

Authors:  Stefano Nardini; Gaetano Cicchitto; Fernando De Benedetto; Claudio F Donner; Mario Polverino; Claudio M Sanguinetti; Alberto Visconti
Journal:  Multidiscip Respir Med       Date:  2014-07-18

10.  National cohort data from Sweden to the National COPD audit in England and Wales: grand designs for quality improvement.

Authors:  Rupert Jones; Michael Roberts
Journal:  Prim Care Respir J       Date:  2014-03
View more
  7 in total

1.  Effectiveness of an Intervention to Improve Management of COPD using the AUDIT Methodology: Results of the Neumo-Advance Study.

Authors:  Javier de Miguel-Díez; Rodrigo Jiménez-García; Ana López de Andrés; Fernando Zaragoza Arnáez
Journal:  Clin Drug Investig       Date:  2019-07       Impact factor: 2.859

2.  Long-Term Outcomes for Chinese COPD Patients After PCI: A Propensity Score Matched, Double-Cohort Study.

Authors:  Yitian Zheng; Yu Qi; Samuel Seery; Wenyao Wang; Wei Zhao; Tao Shen; Lequn Zhou; Jie Yang; Chen Li; Xuliang Wang; Jun Gao; Xiangbin Meng; Erdan Dong; Yi-Da Tang
Journal:  Front Cardiovasc Med       Date:  2022-06-09

3.  Association of Patient and Primary Care Provider Factors with Outpatient COPD Care Quality.

Authors:  Thomas L Keller; Jennifer Wright; Lucas M Donovan; Laura J Spece; Kevin Duan; Nadiyah Sulayman; Alexandria Dominitz; J Randall Curtis; David H Au; Laura C Feemster
Journal:  Chronic Obstr Pulm Dis       Date:  2022-01-27

4.  Testing for alpha-1 antitrypsin in COPD in outpatient respiratory clinics in Spain: A multilevel, cross-sectional analysis of the EPOCONSUL study.

Authors:  Myriam Calle Rubio; Joan B Soriano; José Luis López-Campos; Juan J Soler-Cataluña; Bernardino Alcázar Navarrete; José Miguel Rodríguez González-Moro; Marc Miravitlles; Miriam Barrecheguren; Manuel E Fuentes Ferrer; Juan Luis Rodriguez Hermosa
Journal:  PLoS One       Date:  2018-06-28       Impact factor: 3.240

5.  Assessing the clinical practice in specialized outpatient clinics for chronic obstructive pulmonary disease: Analysis of the EPOCONSUL clinical audit.

Authors:  Myriam Calle Rubio; Juan José Soler-Cataluña; José Luis López-Campos; Bernardino Alcázar Navarrete; José Miguel Rodríguez González-Moro; Joan B Soriano; Manuel E Fuentes Ferrer; Juan Luis Rodriguez Hermosa
Journal:  PLoS One       Date:  2019-02-06       Impact factor: 3.240

6.  Highlights of an Expert Advisory Board on Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AE-COPD) in Latin America.

Authors:  Laura Naranjo; Carlos A Torres-Duque; Daniel Colodenco; Gustavo Lopardo; Pablo Rodriguez; Aldo Agra de Albuquerque-Neto; Rafael J Hernandez-Zenteno; Luis Septien; Reynaldo Chandler; Eduardo Ortega-Barria; Patricia Juliao; Adriana Guzman-Holst
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-08-06

7.  Compliance and Utility of a Smartphone App for the Detection of Exacerbations in Patients With Chronic Obstructive Pulmonary Disease: Cohort Study.

Authors:  Juan Luis Rodriguez Hermosa; Antonia Fuster Gomila; Luis Puente Maestu; Carlos Antonio Amado Diago; Francisco Javier Callejas González; Rosa Malo De Molina Ruiz; Manuel E Fuentes Ferrer; Jose Luis Álvarez Sala-Walther; Myriam Calle Rubio
Journal:  JMIR Mhealth Uhealth       Date:  2020-03-19       Impact factor: 4.773

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.